KURA vs. XNCR, IRWD, AIMT, RARX, ZNTL, VKTX, IONS, OGN, MDGL, and SMMT
Should you be buying Kura Oncology stock or one of its competitors? The main competitors of Kura Oncology include Xencor (XNCR), Ironwood Pharmaceuticals (IRWD), Aimmune Therapeutics (AIMT), Ra Pharmaceuticals (RARX), Zentalis Pharmaceuticals (ZNTL), Viking Therapeutics (VKTX), Ionis Pharmaceuticals (IONS), Organon & Co. (OGN), Madrigal Pharmaceuticals (MDGL), and Summit Therapeutics (SMMT). These companies are all part of the "medical" sector.
Kura Oncology (NASDAQ:KURA) and Xencor (NASDAQ:XNCR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, community ranking, analyst recommendations, earnings and media sentiment.
Kura Oncology has a net margin of 0.00% compared to Xencor's net margin of -82.23%. Xencor's return on equity of -20.29% beat Kura Oncology's return on equity.
Xencor received 89 more outperform votes than Kura Oncology when rated by MarketBeat users. Likewise, 72.89% of users gave Xencor an outperform vote while only 69.01% of users gave Kura Oncology an outperform vote.
Kura Oncology has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500. Comparatively, Xencor has a beta of 0.82, indicating that its stock price is 18% less volatile than the S&P 500.
Kura Oncology currently has a consensus target price of $27.94, indicating a potential upside of 28.39%. Xencor has a consensus target price of $35.43, indicating a potential upside of 62.96%. Given Xencor's higher possible upside, analysts plainly believe Xencor is more favorable than Kura Oncology.
Xencor has higher revenue and earnings than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks.
In the previous week, Kura Oncology and Kura Oncology both had 3 articles in the media. Kura Oncology's average media sentiment score of 1.16 beat Xencor's score of 0.84 indicating that Kura Oncology is being referred to more favorably in the media.
Summary
Xencor beats Kura Oncology on 8 of the 12 factors compared between the two stocks.
Get Kura Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for KURA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kura Oncology Competitors List
Related Companies and Tools
